key: cord-0880609-zalx5mbj
authors: Zandi, Milad; Soltani, Saber
title: Hemagglutinin-esterase cannot be considered as a candidate for designing drug against COVID-19
date: 2021-07-09
journal: Mol Divers
DOI: 10.1007/s11030-021-10272-w
sha: 7b38ba017e3ac9da736f274e70800053d58cb571
doc_id: 880609
cord_uid: zalx5mbj

We read with interest the article by Patel et al. on the identification of potential inhibitors of coronavirus hemagglutinin-esterase. The authors considered hemagglutinin-esterase as a glycoprotein of SARS-CoV-2 and selected hemagglutinin-esterase as a target to identify potential inhibitors using a combination of various computational approaches, and however, SARS-CoV-2 genome lacks hemagglutinin-esterase gene; thus, hemagglutinin-esterase does not exist in SARS-CoV-2 particle. [Image: see text]

In December 2019, a novel betacoronavirus "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) detected in China [1] . SARS-CoV-2 is a member of Coronaviridae family. There are four genera in coronaviruses apha-, beta-, gamma-and deltacoronavirus [2] . Betacoronavirus genera is classified into five subgenera or lineages (Table 1 ) [3] . SARS-CoV-2 is a positive-sense single-strand RNA virus, and the size of its genome is about 30 kb [4] . The 2/3 of genome of SARS-CoV-2 at 5′ end contains two overlapping open reading frames (ORF1a and ORF1b) which encode two polyprotein precursors including pp1a and pp1b, respectively. Two proteases cleave both pp1a and pp1b to produce non-structural proteins. The remaining 3′ third of the genome encodes four structural proteins including spike (S), envelope (E), matrix (M) and nucleocapsid (N), and also, accessory genes are distributed in among the structural genes [4, 5] . Novel coronavirus (n-CoV) as a betacoronavirus of lineage B does not contain hemagglutinin-esterase (HE) [6] [7] [8] [9] [10] . However, betacoronaviruses of lineage A (such as OC43-CoV, HKU1-CoV and Bovine-CoV) harbor HE gene which encodes HE that acts as a receptor-destroying enzyme [11] . Some studies mistakenly reported that SARS-CoV-2 contains HE. Duner et al. stated that some coronaviruses including SARS-COV-2 contain HE [12] , and however, they cited a reference which is published in 1998 Aug [13] , although SARS-CoV-2 is detected in 2019 Dec and lacks HE. In another article, authors reported that betacoronavirus mostly uses HE to link to sialic acid on the glycoprotein surface [14] , and however, betacoronavirus is a genera (Table 1 ) and among betacoronaviruses, viruses which belong to Embecovirus subgenera can code HE as a glycoprotein surface [15] . Aktas A et al. examined the biological activity of Arbidol in the inhibition of HE and spike glycoproteins of SARS-CoV-2 in silico [16] , but according to scientific evidences which are described above, SARS-CoV-2 codes four structural proteins including spike, envelop, membrane and nucleoprotein [17] , and therefore, Arbidol has no such interaction with HE in SARS-CoV-2 infection.

Recently in a published research article, authors presented that genome of SARS-CoV-2 harbors hemagglutinin-esterase gene and encodes HE glycoprotein, authors considered HE as a target for designing drug against SARS-CoV-2 infection [18] , however, according to evidence SARS-CoV-2 genome lacks HE gene and cannot encode HE protein.

Funding No funding.

Conflicts of interest Authors declare no conflicts of interest. 

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges

Coronavirus disease 2019 (COVID-19): current status and future perspectives

Global epidemiology of bat coronaviruses

SARS coronavirus 2: from genome to infectome

Structural and functional conservation of the programmed−1 ribosomal frameshift signal of SARS coronavirus 2 (SARS-CoV-2)

SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes

Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

The nanotechnology-COVID-19 Interface. Nanotechnology-COVID-19 interface

Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays

Role of glycoprotein hemagglutinin-esterase in COVID-19 pathophysiology?

Coronavirus hemagglutinin-esterase and spike proteins coevolve for functional balance and optimal virion avidity

COVID-19 and possible pharmacological preventive options

Coronavirus particle assembly: primary structure requirements of the membrane protein

Antivirals for COVID-19: a critical review

SARS-CoV-2 evolutionary adaptation toward host entry and recognition of receptor O-Acetyl sialylation in virus-host interaction

How do arbidol and its analogs inhibit the SARS-CoV-2?

The role of miRNAs in COVID-19 disease

Identification of potential inhibitors of coronavirus hemagglutinin-esterase using molecular docking, molecular dynamics simulation and binding free energy calculation